Answers are grounded in this paper and cite their sources.
While the majority of myelodysplasia and acute myeloid leukemia (MDS/AML) cases are sporadic, rare familial predisposition syndromes have been delineated and now represent a separate disease entity in the revised World Health Organization (WHO) classification of myeloid neoplasms [ 1 ]. Germline mutations in ~14 disease genes have been uncovered thus far, with GATA2 representing one of the key transcriptional regulators commonly mutated in inherited MDS/AML [ 2 ]. Increasing evidence suggests that aberrations in GATA2 impair its transcription and promoter activation, leading to a loss-of-function, supporting a mechanism of GATA2 haploinsufficiency [ 3 , 4 , 5 ]. Reduced penetrance, the observation that family members carry an identical germline mutation yet display variable clinical manifestations, is common and poses a clinical challenge in the diagnosis and management of familial leukemia's, particularly when identifying “silent” mutation carriers for genetic screening and exclusion as potential stem cell transplant donors [ 6 , 7 ]. Indeed, we have noted that reduced penetrance is a feature among certain GATA2 -mutated MDS/AML families [ 8 ], especially those harboring missense germline mutations such as c.1061C>T (p.Thr354Met) (Table S1 ) although the precise molecular explanation of such occurrence has not been investigated.
No takes yet. Share an insight, caveat, or question.
Seraihi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: